Treatment of blastomycosis with higher doses of fluconazole

Clinical Infectious Diseases

Volumn 25, Issue 2, 1997, Pages 200-205

  Pappas, Peter G ^a   Bradsher, Robert W ^a   Kauffman, Carol A ^a   Cloud, Gretchen A ^a   Thomas, Carolynn J ^a   Campbell Jr , G Douglas ^a   Chapman, Stanley W ^a   Newman, Cheryl ^a   Dismukes, William E ^a  

^a 229 Tinsley Harrison Tower ^*

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; KETOCONAZOLE;

ADULT; AGED; ALOPECIA; ANOREXIA; ARTICLE; BLASTOMYCOSIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEMALE; HUMAN; INDIGESTION; MALE; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; TREATMENT OUTCOME; VOMITING;

EID: 16944362231     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/514539     Document Type: Article

References (20)

1. National Institute of Allergy and Infectious Diseases Mycoses Study Group. Treatment of blastomycosis and histoplasmosis with ketoconazole: results of a prospective randomized clinical trial. Ann Intern Med 1985; 103:861-72.
2. Bradsher RW, Rice DC, Abernathy RS. Ketoconazole therapy for endemic blastomycosis. Ann Intern Med 1985; 103:872-9.
3. Dismukes WE, Bradsher RW Jr, Cloud GC, et al. Itraconazole therapy for blastomycosis and histoplasmosis. Am J Med 1992; 93:489-97.
4. Mangino JE, Pappas PG. Itraconazole for the treatment of histoplasmosis and blastomycosis. Int J Antimicrob Agents 1995; 5:219-25.
5. Kauffman CA. Role of azoles in antifungal therapy. Clin Infect Dis 1996; 22(suppl 2):S148-53.
6. Lyman CA, Sugar AM, Diamond RD. Comparative activities of UK-49,858 and amphotericin B against Blastomyces dermatitidis infections in mice. Antimicrob Agents Chemother 1986; 29:161-2.
7. Galgiani JN. Susceptibility of Candida albicans and other yeasts to fluconazole: relation between in vitro and in vivo studies. Rev Infect Dis 1990; 12(suppl 3):S272-5.
8. Grant SM, Clissold SP. Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses. Drugs 1990; 39:877-916.
9. Stevens DA, Brummer E, McEwen JG, Perlman AM. Comparison of fluconazole and ketoconazole in experimental murine blastomycosis. Rev Infect Dis 1990; 12(suppl 3):S304-6.
10. Pappas PG, Bradsher RW, Chapman SW, et al. Treatment of blastomycosis with fluconazole: a pilot study. Clin Infect Dis 1995; 20:267-71.
11. Toon S, Ross CE, Gokal R, Rowland M. An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole. Dr J Clin Pharmacol 1990; 29:221-6.
12. Lockwood WR, Allison F Jr, Batson BE, Busey JF. The treatment of North American blastomycosis. Ten years' experience. Am Rev Respir Dis 1969; 100:314-20.
13. Busey JF. Blastomycosis. III. A comparative study of 2-hydroxystilbamidine and amphotericin B therapy. Am Rev Respir Dis 1972; 105: 812-8.
14. Sugar AM, Alsip SG, Galgiani JN, et al. Pharmacology and toxicity of high-dose ketoconazole. Antimicrob Agents Chemother 1987; 31: 1874-8.
15. Gallis HA, Drew RH, Pickard WW. Amphotericin B: 30 years of clinical experience. Rev Infect Dis 1990; 12:308-29.
16. Taillan B, Ferrari E, Cosnefroy JY, et al. Favourable outcome of blastomycosis of the brain stem with fluconazole and flucytosine treatment. Ann Med 1992; 24:71-2.
17. Pearson GJ, Chin TWF, Fong IW. Case report: treatment of blastomycosis with fluconazole. Am J Med Sci 1992; 303:313-5.
18. Pitrak DL, Andersen BR. Cerebral blastomycoma after ketoconazole therapy for respiratory tract blastomycosis. Am J Med 1989; 86:713-4.
19. Yancey RW Jr, Perlino CA, Kaufman L. Asymptomatic blastomycosis of the central nervous system with progression in patients given ketoconazole therapy: a report of two cases. J Infect Dis 1991; 164:807-10.
20. Pappas PG, Kauffman CA, Perfect J, et al. Alopecia associated with fluconazole therapy. Ann Intern Med 1995; 123:354-7.